Ilyang Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 2.46%

Ilyang Pharmaceutical Co Ltd (007575) has an Asset Resilience Ratio of 2.46% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩10.93 Billion
≈ $7.41 Million USD Cash + Short-term Investments

Total Assets

₩444.81 Billion
≈ $301.44 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Ilyang Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Ilyang Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Ilyang Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ilyang Pharmaceutical Co Ltd (007575) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩10.93 Billion 2.46%
Total Liquid Assets ₩10.93 Billion 2.46%

Asset Resilience Insights

  • Limited Liquidity: Ilyang Pharmaceutical Co Ltd maintains only 2.46% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Ilyang Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Ilyang Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 48.48%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 15.57%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%

Annual Asset Resilience Ratio for Ilyang Pharmaceutical Co Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Ilyang Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.97% ₩8.49 Billion
≈ $5.76 Million
₩431.21 Billion
≈ $292.23 Million
+0.07pp
2023-12-31 1.90% ₩6.78 Billion
≈ $4.59 Million
₩356.66 Billion
≈ $241.70 Million
+0.81pp
2022-12-31 1.09% ₩5.42 Billion
≈ $3.67 Million
₩498.19 Billion
≈ $337.61 Million
-5.86pp
2021-12-31 6.95% ₩34.34 Billion
≈ $23.27 Million
₩494.27 Billion
≈ $334.96 Million
+6.89pp
2020-12-31 0.06% ₩270.87 Million
≈ $183.56K
₩439.12 Billion
≈ $297.58 Million
+0.05pp
2019-12-31 0.01% ₩43.52 Million
≈ $29.49K
₩437.46 Billion
≈ $296.46 Million
-1.25pp
2018-12-31 1.26% ₩5.46 Billion
≈ $3.70 Million
₩432.25 Billion
≈ $292.93 Million
+0.51pp
2017-12-31 0.76% ₩3.31 Billion
≈ $2.24 Million
₩436.37 Billion
≈ $295.72 Million
+0.75pp
2016-12-31 0.01% ₩43.85 Million
≈ $29.72K
₩431.26 Billion
≈ $292.26 Million
-0.07pp
2015-12-31 0.08% ₩354.85 Million
≈ $240.48K
₩431.63 Billion
≈ $292.51 Million
-0.05pp
2014-12-31 0.13% ₩581.48 Million
≈ $394.06K
₩430.83 Billion
≈ $291.97 Million
--
pp = percentage points

About Ilyang Pharmaceutical Co Ltd

KO:007575 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$90.85 Million
₩134.06 Billion KRW
Market Cap Rank
#19470 Global
#941 in Korea
Share Price
₩7380.00
Change (1 day)
+1.79%
52-Week Range
₩7000.00 - ₩13640.00
All Time High
₩141909.13
About

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more